Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Ambarella Says Co Has ~$17M With SVB

News

Ambarella Says Co Has ~$17M With SVB

-SEC Filing

byBenzinga Newsdesk

March 10, 2023

1 minute read

-SEC Filing

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites To Its Ongoing Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing’s Sarcoma And FET-Rearranged Sarcomas

By Bill Haddad

August 22, 8:33 AM

Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a

SLRX

RGC Resources Q4 EPS $1.01

By Bill Haddad

November 16, 6:17 PM

RGC Resources (NASDAQ:RGCO) reported quarterly earnings of $1.01 per share.

RGCO

Reported Nov 9, Neurocrine Biosciences Provides Development Pipeline Update; Failed To Demonstrate Meaningful Reduction In Seizure Frequency; Failed to Meet Its Primary Endpoint In Patients With Anhedonia In Major Depressive Disorder

By Benzinga Newsdesk

November 10, 12:16 PM

Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure FrequencyPhase 2 Proof-of-Concept Study of NBI-1065846 in Patients with Anhedonia

NBIX

Evercore ISI Group Maintains Outperform on SunPower, Lowers Price Target to $26

By Benzinga Newsdesk

February 14, 10:14 AM

Evercore ISI Group analyst Sean Morgan maintains SunPower (NASDAQ:SPWR) with a Outperform and lowers the price target from $32 to $26.

SPWR

Ambarella Says Co Has ~$17M With SVB

Related Posts

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites To Its Ongoing Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing’s Sarcoma And FET-Rearranged Sarcomas

RGC Resources Q4 EPS $1.01

Reported Nov 9, Neurocrine Biosciences Provides Development Pipeline Update; Failed To Demonstrate Meaningful Reduction In Seizure Frequency; Failed to Meet Its Primary Endpoint In Patients With Anhedonia In Major Depressive Disorder

Evercore ISI Group Maintains Outperform on SunPower, Lowers Price Target to $26